Amgen (CHIX:AMGD) Cyclically Adjusted Revenue per Share: €49.73 (As of Mar. 2026)


CHIX:AMGD Amgen Inc CHIX:AMGD
90 GF Score
Price €285.00
GF Value €325.97
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Amgen Cyclically Adjusted Revenue per Share?

Amgen CHIX:AMGD 90 Cyclically Adjusted Revenue per Share is €49.73 as of Mar. 2026. GuruFocus rates CHIX:AMGD with a GF Score™ of 90/100 and a GF Value™ of €325.97 (Modestly Undervalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Amgen's adjusted revenue per share for the three months ended in Mar. 2026 was €13.703. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €49.73 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Amgen's average Cyclically Adjusted Revenue Growth Rate was 9.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 10.40% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 10.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Amgen was 23.00% per year. The lowest was 8.70% per year. And the median was 14.20% per year.

As of today (2026-07-13), Amgen's current stock price is €285.00. Amgen's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €49.73. Amgen's Cyclically Adjusted PS Ratio of today is 5.73.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Amgen was 8.61. The lowest was 5.09. And the median was 6.91.


Amgen  (CHIX:AMGd) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Amgen's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=285.00/49.73
=5.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Amgen was 8.61. The lowest was 5.09. And the median was 6.91.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Amgen Cyclically Adjusted Revenue per Share Related Terms


Amgen Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Amgen's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amgen Cyclically Adjusted Revenue per Share Chart

Amgen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 40.05 47.29 39.18

Amgen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 45.22 45.77 44.83 39.18 49.73

CHIX:AMGD vs GILD, PFE, BMY: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Amgen's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amgen Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Amgen's Cyclically Adjusted PS Ratio falls into.


CHIX:AMGD
90GF Score
Amgen Inc CHIX:AMGD
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amgen Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Amgen's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=13.703/330.2130*330.2130
=13.703

Current CPI (Mar. 2026) = 330.2130.

Amgen Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 6.696 241.018 9.174
201609 6.876 241.428 9.405
201612 7.621 241.432 10.423
201703 6.895 243.801 9.339
201706 7.007 244.955 9.446
201709 6.608 246.819 8.841
201712 6.753 246.524 9.045
201803 6.335 249.554 8.383
201806 7.858 251.989 10.297
201809 7.796 252.439 10.198
201812 8.543 251.233 11.229
201903 7.856 254.202 10.205
201906 8.518 256.143 10.981
201909 8.653 256.759 11.128
201912 9.342 256.974 12.005
202003 9.387 258.115 12.009
202006 9.309 257.797 11.924
202009 9.258 260.280 11.745
202012 9.338 260.474 11.838
202103 8.532 264.877 10.637
202106 9.404 271.696 11.429
202109 10.000 274.310 12.038
202112 10.742 278.802 12.723
202203 10.280 287.504 11.807
202206 11.616 296.311 12.945
202209 12.488 296.808 13.893
202212 12.000 296.797 13.351
202303 10.599 301.836 11.595
202306 12.008 305.109 12.996
202309 12.023 307.789 12.899
202312 13.970 306.746 15.039
202403 12.782 312.332 13.514
202406 14.404 314.175 15.139
202409 14.135 315.301 14.804
202412 16.039 315.605 16.781
202503 13.933 319.799 14.387
202506 14.710 322.561 15.059
202509 15.023 324.800 15.273
202512 15.545 324.054 15.840
202603 13.703 330.213 13.703

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €49.73 mean?
Amgen (CHIX:AMGD) has a Cyclically Adjusted Revenue per Share of €49.73 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Amgen and its competitors.
Is Amgen's Cyclically Adjusted Revenue per Share too high?
Amgen's current Cyclically Adjusted Revenue per Share is €49.73. Overall, Amgen has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amgen's Cyclically Adjusted Revenue per Share compare to GILD and PFE?
Amgen's Cyclically Adjusted Revenue per Share of €49.73 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Amgen and its competitors. Amgen's current Cyclically Adjusted Revenue per Share is €49.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Based on GuruFocus' analysis, Amgen (CHIX:AMGD) is currently considered Modestly Undervalued. The stock's GF Value™ is €325.97, compared to a current price of €285.00 — trading 12.6% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €49.73. Amgen's overall GF Score™ is 90/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Amgen (CHIX:AMGD), the current Cyclically Adjusted Revenue per Share is €49.73 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amgen (CHIX:AMGD) Overvalued in 2026?

Based on GuruFocus' analysis, Amgen stock appears to be undervalued. The current stock price of €285.00 is trading 12.6% below its estimated GF Value™ of €325.97. GuruFocus considers Amgen to be Modestly Undervalued.

Key valuation signals for CHIX:AMGD:

  • Cyclically Adjusted Revenue per Share: €49.73
  • GF Value™: €325.97 vs. price of €285.00 (12.6% below fair value)
  • GF Score™: 90/100 with 8 warning signs

No single metric tells the full story. See the CHIX:AMGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Amgen Business Description

Address One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
90GF Score

Get the complete analysis for CHIX:AMGD

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€285.00
Price
€325.97
GF Value